XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
R
R

Roche

市场新闻

Reuters - 22小时前

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S
Reuters - 22小时前

Swiss stocks - Factors to watch on September 19

Swiss stocks - Factors to watch on September 19 ZURICH/GDANSK, September 19 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ROCHE HOLDING AG ROG.S Roche says phase III results show Xofluza significantly reduces the transmission of influenza viruses. RICHEMONT CFR.S - 2.75 CHF/shr dividend ECONOMY Swiss August trade balance due at 0600 GMT.
A
R
R
S
Reuters - 23小时前

Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses

BRIEF-Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses Sept 19 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS SHOW XOFLUZA SIGNIFICANTLY REDUCES THE TRANSMISSION OF INFLUENZA VIRUSES DATA FROM CENTERSTONE STUDY SHOWS SINGLE-DOSE XOFLUZA REDUCES TRANSMISSION OF INFLUENZA FROM AN I
R
Reuters - 2天前

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z
Reuters - 4天前

Roche Says FDA Approves Ocrevus Zunovo™

BRIEF-Roche Says FDA Approves Ocrevus Zunovo™ Sept 16 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS THIS APPROVAL IS BACKED BY A DECADE OF PROVEN SAFETY AND EFFICACY DATA OF OCREVUS® IV, WITH OVER
R
Reuters - 6天前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 6天前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 6天前

FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis

BRIEF-FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis Sept 13 (Reuters) - Genentech: FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: ID:nBw29jVlta
R
Reuters - 1周前

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F
Reuters - 1周前

FDA Approves Roche’s Tecentriq Hybreza

BRIEF-FDA Approves Roche’s Tecentriq Hybreza Sept 13 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S TECENTRIQ HYBREZA, THE FIRST AND ONLY SUBCUTANEOUS ANTI-PD-(L)1 CANCER IMMUNOTHERAPY TECENTRIQ HYBREZA PROVIDES PATIENTS AND PHYSICIANS WITH GREATER FLEXIBILITY OF TREATMENT OPTIONS WHILE SHOWING SAFETY AND EFFICACY CONSISTENT WITH INT
R
Reuters - 1周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 1周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. Reporting by Urvi Dugar; Editing by Subhranshu Sahu
R
Reuters - 1周前

FDA Approves Genentech’S Tecentriq Hybreza, The First And Only Subcutaneous Anti-Pd-(L)1 Cancer Immunotherapy

BRIEF-FDA Approves Genentech’S Tecentriq Hybreza, The First And Only Subcutaneous Anti-Pd-(L)1 Cancer Immunotherapy Sept 12 (Reuters) - Roche Holding AG ROG.S : FDA APPROVES GENENTECH’S TECENTRIQ HYBREZA, THE FIRST AND ONLY SUBCUTANEOUS ANTI-PD-(L)1 CANCER IMMUNOTHERAPY ROCHE HOLDING AG - FDA APPROVES GENENTECH'S TECENTRIQ HYBREZA FOR SUBCUTANE
R
Reuters - 1周前

FDA Approves atezolizumab And hyaluronidase-tqjs For Subcutaneous Injection

BRIEF-FDA Approves atezolizumab And hyaluronidase-tqjs For Subcutaneous Injection Sept 12 (Reuters) - FDA: FDA APPROVES ATEZOLIZUMAB AND HYALURONIDASE-TQJS FOR SUBCUTANEOUS INJECTION
R
Reuters - 1周前

Roche shares knocked by concern over side effects in obesity pill trial

UPDATE 1-Roche shares knocked by concern over side effects in obesity pill trial Roche shares fall 3.5% Early study trial showed high rate of temporary side effects JP Morgan analysts say heart rate increase is as a concern Roche plans slower ramp-up of pill dose in next trial Updates share price in paragraph 2, further details on side effects in pill trial in paragraphs 6 and 8 FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S dropped to a two-month low on Thursday after an experimental weig
J
P
R
Reuters - 1周前

Roche shares drop on side effects result in early-stage obesity pill trial

Roche shares drop on side effects result in early-stage obesity pill trial FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial .
P
R
Reuters - 1周前

Roche slides on side effects concerns for its weigh-loss pill

BUZZ-Roche slides on side effects concerns for its weigh-loss pill ** Shares in Roche ROG.S drop around 4%, with analysts pointing to concerns around side effects of its experimental weight-loss pill, CT-996 ** J.P.Morgan says in a note that the CT-996 tolerability data raises questions on overall product profile, with high rates of side effects th
R
Reuters - 1周前

Swiss stocks - Factors to watch on September 12

Swiss stocks - Factors to watch on September 12 ZURICH/GDANSK, Sep 12(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: Roche ROG.S Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
B
R
S
Reuters - 1周前

Roche says early-stage obesity pill results were based on just six patients

UPDATE 1-Roche says early-stage obesity pill results were based on just six patients Adds detail of trial in paragraph 6, company comment in paragraph 7, further detail in paragraphs 8-10 FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
P
R

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。